Related Experiment Video
Updated: May 22, 2026
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
Published on: September 20, 2020
Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of
Cristina Sottani1, Guido Poggi, Pietro Quaretti
1Laboratory for Environmental and Toxicological Testing, IRCCS Fondazione S. Maugeri, Istituto Scientifico di Pavia, Pavia, Italy.
Aim:
The purpose of this study was the pharmacokinetic (PK) profile assessment in the serum of patients affected by hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE) with drug-eluting beads.
Patients And Methods:
This study included 20 patients, 12 treated with DC Bead® and 8 with HepaSphere Microsphere®, preloaded with epirubicin. No patient randomization was used for the inclusion in one group or in the other. Peripheral blood samples were obtained from all patients after the treatment, until 24 hours past the procedure.
Results:
The pharmacokinetic study showed low peak serum epirubicin concentrations with greater drug exposure for the DC Bead® group (p<0.05). The highest drug concentration after microsphere injection was observed at 5 minutes in all 20 patients. In the time interval between 1 and 24 hours after TACE, persisting levels of epirubicin were detected in peripheral blood samples.
Conclusion:
A persistent and sustained drug elution for both types of microparticles was found.
More Related Videos
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
08:41Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
